268 related articles for article (PubMed ID: 31562135)
21. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Rampal R; Al-Shahrour F; Abdel-Wahab O; Patel JP; Brunel JP; Mermel CH; Bass AJ; Pretz J; Ahn J; Hricik T; Kilpivaara O; Wadleigh M; Busque L; Gilliland DG; Golub TR; Ebert BL; Levine RL
Blood; 2014 May; 123(22):e123-33. PubMed ID: 24740812
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of the JAK/STAT signaling through erythropoietin receptor and thrombopoietin receptor using a systems approach.
Won HH; Park I; Lee E; Kim JW; Lee D
BMC Bioinformatics; 2009 Jan; 10 Suppl 1(Suppl 1):S53. PubMed ID: 19208156
[TBL] [Abstract][Full Text] [Related]
23. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
[TBL] [Abstract][Full Text] [Related]
24. Current approaches to challenging scenarios in myeloproliferative neoplasms.
Zimran E; Hoffman R; Kremyanskaya M
Expert Rev Anticancer Ther; 2018 Jun; 18(6):567-578. PubMed ID: 29575945
[TBL] [Abstract][Full Text] [Related]
25. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
Masubuchi N; Araki M; Yang Y; Hayashi E; Imai M; Edahiro Y; Hironaka Y; Mizukami Y; Kihara Y; Takei H; Nudejima M; Koike M; Ohsaka A; Komatsu N
Leukemia; 2020 Feb; 34(2):499-509. PubMed ID: 31462733
[TBL] [Abstract][Full Text] [Related]
26. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
27. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
28. The Molecular Genetics of Myeloproliferative Neoplasms.
Marneth AE; Mullally A
Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548225
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J; Mead AJ
Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
[TBL] [Abstract][Full Text] [Related]
30. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
31. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.
Jia R; Kralovics R
Int J Hematol; 2020 Feb; 111(2):182-191. PubMed ID: 31741139
[TBL] [Abstract][Full Text] [Related]
32. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
33. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.
Jia R; Balligand T; Atamanyuk V; Nivarthi H; Xu E; Kutzner L; Weinzierl J; Nedelec A; Kubicek S; Lesyk R; Zagrijtschuk O; Constantinescu SN; Kralovics R
Blood; 2021 Apr; 137(14):1920-1931. PubMed ID: 33202418
[TBL] [Abstract][Full Text] [Related]
34. A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia.
Goyal H; Chachoua I; Pecquet C; Vainchenker W; Constantinescu SN
Blood Rev; 2020 Jul; 42():100712. PubMed ID: 32660739
[TBL] [Abstract][Full Text] [Related]
35. [Clinical application of gene mutation information in myeloproliferative neoplasms].
Takenaka K
Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
[TBL] [Abstract][Full Text] [Related]
36. Myeloproliferative neoplasm stem cells.
Mead AJ; Mullally A
Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
[TBL] [Abstract][Full Text] [Related]
37. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.
Cahu X; Constantinescu SN
Curr Hematol Malig Rep; 2015 Dec; 10(4):335-43. PubMed ID: 26370832
[TBL] [Abstract][Full Text] [Related]
39. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.
Pecquet C; Chachoua I; Roy A; Balligand T; Vertenoeil G; Leroy E; Albu RI; Defour JP; Nivarthi H; Hug E; Xu E; Ould-Amer Y; Mouton C; Colau D; Vertommen D; Shwe MM; Marty C; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2019 Jun; 133(25):2669-2681. PubMed ID: 30902807
[TBL] [Abstract][Full Text] [Related]
40. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]